Review anchor
PBMC
CELL-LINE · Homo sapiens
As of 2026-09-13
Evidence Snapshot
PBMC
CHEMBL613107
CELL-LINE
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats PBMC as ChEMBL target CHEMBL613107. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL613107
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why PBMC matters
PBMC is reviewed as PBMC; the current evidence base includes 44 approved drugs, 5308 compounds, and 1765 assays, with lead potency reaching pChEMBL 11.0.
Protein context
PBMC
PBMC
Review this target as PBMC.
Protein source · UniProt accession via ChEMBL component mappingDisease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 44 approved drugs, 5308 compounds, and 1765 assays for this target. The dominant activity type is IC50. CHEMBL570015 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL570015 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
44 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why PBMC matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
5308
Total Compounds
1765
Total Assays
44
Approved Drugs
IC50: 3652.0, EC50: 374.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL570015
|
11.0 | IC50 | Clinical |
|
|
No preferred name
CHEMBL475397
|
10.9 | IC50 | — |
|
|
No preferred name
CHEMBL516398
|
10.8 | IC50 | — |
|
|
No preferred name
CHEMBL514182
|
10.8 | IC50 | — |
|
|
No preferred name
CHEMBL3288029
|
10.7 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
GIVINOSTAT
CHEMBL1213492
|
2024 |
|
|
CRISABOROLE
CHEMBL484785
|
2016 |
|
|
APREMILAST
CHEMBL514800
|
2014 |
|
|
POMALIDOMIDE
CHEMBL43452
|
2013 |
|
|
TOFACITINIB
CHEMBL221959
|
2012 |
|
|
RUXOLITINIB
CHEMBL1789941
|
2011 |
|
|
ROFLUMILAST
CHEMBL193240
|
2010 |
|
|
PLERIXAFOR
CHEMBL18442
|
2008 |
|
|
FLUTICASONE FUROATE
CHEMBL1676
|
2007 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
LENALIDOMIDE
CHEMBL848
|
2005 |
|
|
MYCOPHENOLIC ACID
CHEMBL866
|
2004 |
|
|
NEVIRAPINE
CHEMBL57
|
1996 |
|
|
LAMIVUDINE
CHEMBL141
|
1995 |
|
|
TACROLIMUS ANHYDROUS
CHEMBL269732
|
1994 |
|
|
BUDESONIDE
CHEMBL1370
|
1994 |
|
|
FLUTICASONE PROPIONATE
CHEMBL1473
|
1990 |
|
|
ZIDOVUDINE
CHEMBL129
|
1987 |
|
|
CYCLOSPORINE
CHEMBL160
|
1983 |
|
|
CALCITRIOL
CHEMBL846
|
1978 |
|
|
DOXORUBICIN
CHEMBL53463
|
1974 |
|
|
AZATHIOPRINE
CHEMBL1542
|
1968 |
|
|
DEXAMETHASONE
CHEMBL384467
|
1958 |
|
|
MERCAPTOPURINE ANHYDROUS
CHEMBL1425
|
1953 |
Source Header